Physician profile
Luis P Leyva
NPI 1669417366
$4,958.20
in general payments reported to CMS, 2019-2025
28 companies · $501 in 2025
The $501 reported for 2025 was more than what 80% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $463 · 2020: $189 · 2021: $217 · 2022: $647 · 2023: $2,467 · 2024: $476 · 2025: $501.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,155 · Travel and Lodging: $1,275 · Education: $13.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,155.45 |
| Travel and Lodging | $1,274.66 |
| Education | $13.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Modernatx, INC. | $1,795.50 | 2023 | |
| Hologic Sales and Service, LLC | $770.18 | 2019-2025 | Acessa Provu System, Thinprep 2000 Processor, Aptima |
| Abbvie INC. | $616.00 | 2019-2022 | |
| Mayne Pharma Commercial LLC | $411.23 | 2022-2025 | |
| Astellas Pharma US INC | $297.84 | 2023-2025 | Veozah |
| Millicent US INC | $119.98 | 2024-2025 | Intrarosa, Femring, Femlyv |
| Allergan, INC. | $112.80 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $110.86 | 2019-2025 | |
| Medicem INC. | $102.48 | 2022 | |
| Daiichi Sankyo INC. | $98.60 | 2019-2022 | |
| Pfizer INC. | $76.86 | 2022-2025 | |
| Myovant Sciences INC. | $68.79 | 2022 | |
| Therapeuticsmd, INC. | $59.31 | 2019-2021 | |
| Roche Diagnostics Corporation | $39.69 | 2019 | |
| Organon LLC | $37.95 | 2022-2024 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avion Pharmaceuticals | $37.39 | 2020-2022 | |
| Biogen, INC. | $27.64 | 2025 | Zurzuvae |
| Duchesnay USA Incorporated | $26.68 | 2019 | |
| Exeltis, USA INC. | $21.19 | 2024 | Slynd |
| Agile Therapeutics, INC. | $18.22 | 2021 | |
| Axonics, INC. | $17.88 | 2023 | Axonics |
| Bard Peripheral Vascular, INC. | $16.97 | 2022 | |
| Mylan Pharmaceuticals INC. | $16.40 | 2019 | |
| Evofem Biosciences, INC. | $16.05 | 2021 | |
| Exact Sciences Corporation | $14.75 | 2025 | The Cologuard Plus Collection Kit |
| Kowa Pharmaceuticals America, INC. | $13.85 | 2023 | Seglentis |
| Merck Sharp & Dohme LLC | $13.11 | 2024 | Gardasil 9, Gardasil |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luis Leyva listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.